The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).
 
Arpit Rao
Honoraria - Bayer; Cardinal Health; Lilly; Sanofi
Consulting or Advisory Role - Lilly (Inst)
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Clovis Oncology (Inst); Lilly (Inst); Pfizer/Astellas (Inst); Seattle Genetics/Astellas (Inst)
 
Glenn Heller
Research Funding - Janssen Diagnostics
 
Charles J. Ryan
Honoraria - Bayer; Janssen Oncology
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Clovis Oncology (Inst); Dendreon; Myovant Sciences; Roivant
Research Funding - Clovis Oncology (Inst); Genzyme (Inst)
 
David James VanderWeele
Consulting or Advisory Role - Clovis Oncology; Exelixis
Research Funding - AstraZeneca (Inst); Department of Defense-Prostate Cancer Research Program; Fortis (Inst); Prostate Cancer Foundation
 
Lionel D Lewis
Honoraria - G1 Therapeutics
Consulting or Advisory Role - G1 Therapeutics
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Polynoma (Inst)
Expert Testimony - Amgen
 
Alan Tan
Stock and Other Ownership Interests - Adaptimmune; Aprea AB; Bluebird Bio; crispr therapeutics; Editas Medicine; FATE Therapeutics; Geron; Iovance Biotherapeutics; Jounce Therapeutics; MEI Pharma; Myovant Sciences; Nektar; Sangamo Therapeutics
Honoraria - AstraZeneca; Bristol Myers Squibb Foundation; Verastem
Consulting or Advisory Role - Exelixis; Foundation Medicine
Speakers' Bureau - AstraZeneca; bristol myers squibb; verastem
 
Colleen Watt
No Relationships to Disclose
 
Ronald C. Chen
Consulting or Advisory Role - Abbvie; Accuray; Accuray; Bayer; Blue Earth Diagnostics; Genentech; Medivation/Astellas; Myovant Sciences; Pfizer
Research Funding - Accuray
 
Manish Kohli
Honoraria - Advanced Accelerator Applications
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Genapsys
Travel, Accommodations, Expenses - Celgene
 
Pedro C. Barata
Consulting or Advisory Role - Bayer; BMS; Caris Life Sciences; Clovis Oncology (Inst); Dendreon (Inst); Eisai; EMD Serono; Pfizer
Research Funding - Blue Earth Diagnostics (Inst)
 
Benjamin Adam Gartrell
Honoraria - Janssen
Consulting or Advisory Role - Janssen
 
Robert Grubb
Employment - Anthem Foundation (I)
Stock and Other Ownership Interests - Anthem (I)
Research Funding - FKD Therapies; GlaxoSmithKline
 
Amylou C. Dueck
Patents, Royalties, Other Intellectual Property - Royalties from licensing fees for a patient symptom questionnaire (MPN-SAF)
 
Yujia Wen
No Relationships to Disclose
 
Michael J. Morris
Stock and Other Ownership Interests - Doximity
Consulting or Advisory Role - Advanced Accelerator Applications; Athenex; Bayer; Curium Pharma; Endocyte; Exelixis; Johnson & Johnson; Lantheus Medical Imaging; NCCN; Novartis; ORIC Pharmaceuticals; Progenics
Research Funding - Bayer (Inst); Corcept Therapeutics (Inst); Endocyte (Inst); Janssen (Inst); Progenics (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Endocyte; Fujifilm